Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia:a Multinational Point Prevalence Study of Hospitalised Patients

Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients

Time structure analysis of leg movements during sleep in REM sleep behavior disorder

none6noneManconi M.; Ferri R.; Zucconi M.; Fantini M.L.; Plazzi G.; Ferini-Strambi L.Manconi M.; Ferri R.; Zucconi M.; Fantini M.L.; Plazzi G.; Ferini-Strambi L

Corrigendum to “Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease” (Dig. Liver Dis. (2016) 48(4) (360–370))

In the last paragraph of Section 1, the sentence \u201cVDZ is a monoclonal antibody blocking the \u3b14\u3b27 integrin which is selectively expressed by the vascular endothelium in the gastrointestinal tract [7]\u201d should be replaced with: \u201cVDZ is a monoclonal antibody blocking the \u3b14\u3b27 integrin which is selectively expressed by the activated GUT homing lymphocytes [7]\u201d. Mariabeatrice Principi, Gastroenterology Section, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy, should have been listed in Appendix A (Members of the GIVI Study Group)